Accreditation

Continuing Medical Education Information

 

Target Audience

Endocrinologists, cardiologists, nephrologists, gastroenterologists/liver disease specialists, physician assistants, nurse practitioners, nurses, and primary care physicians.

 

Learning Objectives

By the end of the meeting, participants will be able to:

  • Utilize the latest clinical practice guidelines on cardiometabolic disease, including Type 2 diabetes and cardiovascular risk/heart failure, obesity, and chronic
  • kidney disease.              
  • Discuss the key characteristics of evidence-based assessment and treatment options for patients with cardiometabolic disease   
  • Describe barriers in being able to manage the risk factors as well as the ability of patients to carry through recommendations for a healthier lifestyle.   
  • Explain cardiovascular risk management approaches that remain controversial without consensus as to best approach.   

 

Accreditation and Designation Statements

ACCME
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this “Other” for a maximum of 11.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.

Please allow two weeks for MOC points to appear within your account on the ABIM website. Participation information will be shared.

 

Disclosure and Conflicts of Interest Policy:

The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence based  clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.

 

Planning Committee

Betul Hatipoglu, MD (Program Chair)
David Lieb, MD, FACE, FACP
Monica Agarwal, MD, FACE, MEHP
Julia Blanchette, PhD, RN, CDCES
Nicholas Galloway, RN, CDCES
Diana Isaacs, PharmD, CDCES
Loretta Planavsky, NP

 

Planning Committee Disclosures

Name Relevant Financial Relationship  Ineligible Company  
Julia Blanchette, PhD, RN, CDCESAdvisorCardinal Health/Edgepark; Lifescan/Prevention Bio
 Contracted ResearchTandem
 Consulting FeesWellDoc
 Northern Ohio and Michigan Board of DirectorsJDRF
Nicholas Galloway, RN, CDCESBoard of DirectorsADCES
 Consulting FeesTidepool
Diana Isaacs, PharmD, CDCESSpeakers bureau, over $10,000Abbott; Dexcom; Medtronic
 Consulting Fees  Insulet; Lifescan 
 SpeakerBayer; Novo Nordisk
 Board memberADCES
 Professional Practice CommitteeADA

 

All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

Faculty Disclosures

Name Relevant Financial Relationship  Ineligible Company  
Richard Auchus, MD, PhD, FACEConsulting FeesAdrenas
 Consulting Fees, Contracted ResearchCorcept Therapeutics Inc.
 Consulting FeesCrinetics Pharmaceuticals
 Contracted ResearchDiurnal, LTD
 Consulting FeesH Lundbeck A/S
 Consulting FeesJanssen
 Research Grant, includes principal investigator, collaborator or consultant and pending grants as well as grants already receivedNeurocrine
 Consulting Fees, Contracted ResearchNovartis
 Consulting FeesPhase Bio
 Consulting FeesQuest Diagnostics
 Consulting FeesRecordati Rare Diseases
 Research Grant, includes principal investigator, collaborator or consultant and pending grants as well as grants already receivedSpruce Biosciences
 Research Grant, includes principal investigator, collaborator or consultant and pending grants as well as grants already receivedStrongbridge
Lawrence Blonde, MD, FACE, MACEConsulting FeesAstraZeneca
 Consulting FeesCorcept Therapeutics Inc.
 Honoraria, Consulting FeesGilead Sciences, Inc.
 Honoraria, speakerJanssen
 Consulting FeesLyndra Therapeutics
 Consulting FeesMerck
 Consulting Fees, Research SupportNovo Nordisk
 Consulting FeesSalix
 Honoraria, Consulting Fees, Research SupportSanofi
Ralph A. DeFronzo, BMS, MD, MS, BSHonoraria, Consulting Fees, Research SupportAstraZeneca
 Consulting FeesBayer
 Consulting Fees, Research SupportBoehringer Ingelheim
 Research Grant, includes principal investigator, collaborator or consultant and pending grants as well as grants already receivedMerck
 Consulting FeesNovo Nordisk
Kenneth Izuora, MD, MBA, FACEUniversity Grants/Research SupportNovo Nordisk
Susheel Patil, MD, PhD, ATSFHonorariaAmerican Board of Internal Medicine
 HonorariaCHEST
Joseph Vassalotti, MDConsulting FeesRenalytix, plc
Max Nieuwdorp, MDOwnership InterestCaelus Health
 Contracted ResearchTandem
 Consulting FeesWellDoc
 Northern Ohio and Michigan Board of DirectorsJDRF

 

All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

Commercial Supporters

This activity is supported by an independent educational grant from:

Pfizer-Merck Alliance